Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service
Open Access
Abstract
Objectives This study was conducted to evaluate the ability of risk assessment to predict healthcare resource utilisation (HCRU), costs, treatments, health-related quality of life (HRQoL) and survival in patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH). Design Retrospective observational study. Setting Pulmonary hypertension referral centre in the UK. Participants Adults diagnosed with CTEPH between 1 January 2012 and 30 June 2019 were included. Cohorts were retrospectively defined for operated patients (received pulmonary endarterectomy (PEA)) and not operated; further subgroups were defined based on risk score (low, intermediate or high risk for 1-year mortality) at diagnosis. Primary and secondary outcome measures Demographics, clinical characteristics, comorbidities, treatment patterns, HRQoL, HCRU, costs and survival outcomes were analysed. Results Overall, 683 patients were analysed (268 (39%) operated; 415 (61%) not operated). Most patients in the operated and not-operated cohorts were intermediate risk (63%; 53%) or high risk (23%; 31%) at diagnosis. Intermediate-risk and high-risk patients had higher HCRU and costs than low-risk patients. Outpatient and accident and emergency visits were lower postdiagnosis for both cohorts and all risk groups versus prediagnosis. HRQoL scores noticeably improved in the operated cohort post-PEA, and less so in the not-operated cohort at 6–18 months postdiagnosis. Survival at 5 years was 83% (operated) and 49% (not operated) and was lower for intermediate-risk and high-risk patients compared with low-risk patients. Conclusions Findings from this study support that risk assessment at diagnosis is prognostic for mortality in patients with CTEPH. Low-risk patients have better survival and HRQoL and lower HCRU and costs compared with intermediate-risk and high-risk patients.Keywords
Funding Information
- Actelion Pharmaceuticals Ltd (Not applicable)
This publication has 37 references indexed in Scilit:
- Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk FactorsAnnals of the American Thoracic Society, 2016
- Quality of life in patients with chronic thromboembolic pulmonary hypertensionEuropean Respiratory Journal, 2016
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertensionEuropean Respiratory Review, 2015
- Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countriesBMC Health Services Research, 2014
- emPHasis-10: development of a health-related quality of life measure in pulmonary hypertensionEuropean Respiratory Journal, 2013
- Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registryInternational Journal of Cardiology, 2013
- Riociguat for the Treatment of Chronic Thromboembolic Pulmonary HypertensionNew England Journal of Medicine, 2013
- The cost to managed care of managing pulmonary hypertensionJournal of Medical Economics, 2012
- Survival plots of time-to-event outcomes in clinical trials: good practice and pitfallsThe Lancet, 2002